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1- Abstract 
Morphine is an analgesic alkaloid used to relieve severe pain, and irreversible binding of morphine 
to specific unknown proteins has been previously observed. In the brain, changes in the expression of 
energy metabolism enzymes contribute to behavioural abnormalities during chronic morphine 
treatment. Creatine kinase B (CK-B) is a key enzyme involved in brain energy metabolism. CK-B also 
corresponds to the imidazoline-binding protein I2 which binds dopamine (a precursor of morphine 
biosynthesis) irreversibly. Using biochemical approaches, we show that recombinant mouse CK-B 
possesses a µM affinity for morphine and binds to morphine in vitro. The complex formed by CK-B 
and morphine is resistant to detergents, reducing agents, heat treatment and SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). CK-B-derived peptides CK-B1-75 and CK-B184-258 were identified as two 
specific morphine binding-sites. In vitro, morphine (1-100 μM) significantly reduces recombinant CK-
B enzymatic activity. Accordingly, in vivo morphine administration (7.5 mg/kg, i.p.) to mice 
significantly decreased brain extract CK-B activity compared to saline-treated animals. Together, these 
results show that morphine strongly binds CK-B and inhibits its activity in vitro and in vivo.  
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2- Background  
Morphine, an alkaloid from Papaver somniferum, is used to relieve pain in multiple clinical settings. 
In addition to its analgesic properties, morphine decreases intestinal motility, suppresses cough and has 
vasodilatory effects {Andersen, 2003 #5023}. It influences many other physiological processes and 
notably decreases ATP availability in specific brain structures [3]. In addition, endogenous morphine 
has been characterized in numerous mammalian cells and tissues, and its structure is identical to that 
of morphine isolated from the poppy (for review [1]).  
Only a few unspecific morphine-binding proteins with low affinity have been identified so far and 
include serum albumin [4; 5]. In the past, our laboratory has demonstrated that the 
phosphatidylethanolamine-binding protein (PEBP) [6] binds to morphine-6-glucuronide (M6G) and 
morphine-3-glucuronide (M3G) with an affinity equal to that of its reference ligand, 
phosphatidylethanolamine, but has no affinity for morphine [7]. In addition to these low affinity 
binding-proteins, covalent binding of morphine to proteins has been proposed to result in irreversible 
binding to insoluble tissue components after administration [8; 9; 10].  
The implication of the imidazoline system, and particularly the I2-binding site (I2B) [11], in the 
modulation of morphine-induced analgesia and morphine analgesic tolerance has been documented 
[12; 13]. Interestingly, creatine kinase B (CK-B) represents the main I2B site for imidazoline and its 
derivatives (clonidine, guanfacine…) [11; 14]. Molecular modelling using the crystal structure of 
chicken CK-B and the irreversible ligand BU990006-binding site has indicated the importance of Thr71, 
Val72, Val75, Leu201, Leu202, Cys283 and Ser285 in this interaction [14]. Dopamine, a morphine precursor 
in plants and mammals [1], has been shown to covalently bind to CK-B [15]. CK-B also forms highly 
stable complexes with ankyrin repeat and SOCS box protein 9 (ASB9) [16]. 
CK-B is a 42 kDa protein expressed in neurons, oligodendrocytes and astrocytes of the central 
nervous system (CNS) [17]. Different CK isoenzymes exist in the cytoplasm as dimers or multimers 
in specific cells: CK-BB in the brain, CK-MM in muscles and CK-MB in the heart [18]. CK catalyzes 
the reversible phosphorylation of creatine by ATP to produce phosphocreatine and ADP. 
Mitochondrial isoforms of CK form phosphocreatine from ATP, whereas cytoplasmic CK isoenzymes 
form ATP from phosphocreatine. 
In the present study, we have investigated whether CK-B might represent a morphine-binding protein. 
Recombinant mouse CK-B (rCK-B) and mouse CK-B-derived synthetic peptides, together with 
biochemistry approaches, were used to characterize the affinity of potential morphine-binding sites. To 
assess the functional significance of CK-B/morphine interactions, the impact of morphine on rCK-B 
activity was studied in vitro and in vivo. 
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3- Material and Methods  
3.1- Experimental design 
Our animal study is reported in accordance with the ARRIVE Guidelines for reporting experiments 
involving animals [19]. Experiments were carried out in a randomised and blind manner, and statistical 
analyses were done prior to revealing treatment groups. At least three technical replicates were used 
for in vitro experiments. Mice were assigned an identity number and assigned to groups randomly so 
that the experimenter was blind to treatment. 
 
3.2- Drugs 
Morphine base was purchased from Euromedex (Souffelweyersheim, France). A stock solution of 35 
mM morphine was prepared by dissolving morphine in H2O after adding an equimolar concentration 
of HCl. Codeine monohydrate, morphine-3-β-D-glucuronide and morphine-6-β-D-glucuronide 
dihydrate powders were purchased from Sigma-Aldrich (Lyon, France) and dissolved in H2O to 
prepare stock solutions. Working concentrations for in vitro and in vivo experiments were prepared 
from the stock on the day of experiment. When necessary, the pH of the working solutions was 
adjusted to 7.4 with NaOH before use. 
 
3.3- Animals 
All procedures were performed in accordance with European directives (86/609/EEC) and were 
approved by the regional ethics committee and the French Ministry of Agriculture (license No. 
00456.02 to Y.G.). Experiments were performed with C57BL/6 mice (45 day-old adult male, 24 ± 3g; 
Charles River, L’Arbresle, France). Animals were given food and water ad libitum, and maintained in 
a 12h light–dark cycle at a room temperature of 22°C ± 2°C. Cage bedding was from Anibed 
(Pontvallain, France; reference AB3) and food from SAFE (Augy, France; reference A04). Mice were 
kept group-housed at 5 per cage (Type II cage, 370cm2, height 14cm).  
 
3.4- Drug injections 
Mice were weighed and then i.p. injected (light phase at 10AM) with a single dose of 7.5 mg/kg 
morphine or an equivalent volume of saline (NaCl 0.9% in H2O). The volume of injection was 240 ± 
30 µL for mice weighing 24 ± 3g. After 90 min, mice were anaesthetized with a solution of ketamine 
and xylazine (17 mg/mL ketamine and 2.5 mg/mL xylazine, 4 mL/kg i.p.; Centravet, Taden, France). 
After 5 min, adequate anaesthesia was ensured by pinching the hind paws and observing no reflex 
response. Animals were then euthanized by decapitation. Brains were then collected and frozen at -
80°C. 
 
3.5- Preparation of brain extracts from morphine and saline-treated mice 
Brains from morphine- and saline-treated mice were homogenised with an Ultra Turrax instrument 
(Ika, Staufen, Germany) in 1 ml of H2O containing protease inhibitors (cOmplete Mini, EDTA-free, 
Roche, Basel, Switzerland). The homogenates were then sonicated (2 times 10 s, 90W) with a Vibra 
Cell apparatus (Sonics, Newtown, U.S.A.) and centrifuged (14,000 x g, 30 min) at 4°C. Supernatants 
were recovered and protein concentration was determined using the Bradford method (Protein Assay, 
Bio-Rad, Marnes-la-Coquette, France). Samples were then frozen at -80°C until further use. 
 
3.6- Production of the mouse rCK-B  
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The N-terminal His-tagged cDNA coding region for the mouse Ckb (residues 1-318, accession 
number NM_021273; ref. MR205953, Origene, Herford, Germany) was cloned into the vector pET15b 
(CIGEx, CEA, Fontenay aux Roses, France). The N-terminal hexahistidine-tagged fusion protein was 
expressed in Escherichia coli BL21 (DE3). Cells were grown in LB medium (Euromedex) at 37°C 
until an A600 of 0.4 and subsequently induced for 3 h at 37°C with 0.1 mM isopropyl 1-thio-D-
galactopyranoside (Euromedex). Harvested bacterial pellets were resuspended in buffer containing 
isopropyl thio-β-d-galactoside (IPTG; Euromedex). The cell pellets were resuspended in binding buffer 
(10 mM Tris-HCl, 300 mM NaCl, 10% glycerol, 2 mM CHAPS and 10 mM imidazole, pH 8.0; 
Euromedex), lysed by sonication on ice (8 x 30 s, 90 W) and then clarified by centrifugation (20,000 
x g, 50 min, 4°C). The cleared supernatant was loaded on a nickel-Hitrap column (GE Healthcare; 
Aulnay Sous Bois, France). The protein was eluted using 50 and 250 mM imidazole (10 mM Tris-HCl, 
300 mM NaCl, pH 8.0; Euromedex). The protein was then dialyzed 12 h at 4°C against a buffer 
containing 10 mM Tris, and 150 mM NaCl (pH 8). The purity and homogeneity of the protein were 
assessed by SDS-PAGE (see below).  
 
3.7- Enzyme-Linked ImmunoSorbent Assay (ELISA) 
ELISAs were performed to determine the affinity and specificity of the binding of mouse rCK-B and 
its derived peptides to opiate alkaloids. 96-well plates (NUNC, Roskilde, Denmark) were coated for 1 
h at 37°C with 100 μl of a solution of CK-B-derived peptides or rCK-B (10 µg/ml) in carbonate-
bicarbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6). After three washes with 100 mM 
phosphate buffer pH 7.4 (PT buffer; 5 min), the wells were incubated for 30 min with 200 μl of BSA 
diluted in PT buffer (5%, w/v; PT-BSA buffer) to saturate non-specific sites. After saturation, wells 
were incubated for 1 h with 100 μl of morphine, M6G, M3G or codeine, diluted in H2O at increasing 
concentrations. The plate was then washed three times with PT buffer, and 100 μl of the mouse primary 
anti-morphine antibody (which detects morphine, codeine, M3G and M6G according to the 
manufacturer’s antibody datasheet) diluted in PT-BSA buffer (1:2,000, v/v; 3A6, ref AMM00033; 
Aviva System Biology, San Diego, USA) were added. After three more washes with PT buffer, 100 μl 
of the secondary antibody in PT-BSA buffer (HRP-conjugated donkey anti-mouse IgG, P.A.R.I.S. 
CliniSciences, Nanterre, France; 1:500, v/v) were added and incubated for 30 min at room temperature. 
After two washes with PT buffer, followed by two washes with a pH 7.5 phosphate-citrate-0.05% 
Tween 20 buffer (10 min), revelation was performed with 200 μl of a 1-Step Ultra TMB substrate 
solution (3,3’,5,5’ tetramethylbenzidine, Fischer Scientific). After 15 min of incubation at RT, the 
reaction was stopped by the addition of 50 µl of 2N hydrochloric acid. Optical density was determined 
at 450 nm with a Multiskan EX plate reader (Thermo Life Sciences, Cergy Pontoise, France). Each 
ELISA points were tested in triplicate in three independent experiments. All samples with a triplicate 
CV>10% were retested to obtain a CV below or equal to 10%. 
 
3.8- Association assays 
Association assays were performed with 0.5 µg of the mouse rCK-B in the presence of 1 or 5 µg of 
morphine, in a final volume of 10 µl incubated during 15 min at 37 °C. Samples were diluted 1:2 with 
the gel-loading buffer (see below). 
 
3.9- Gel electrophoresis 
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Proteins were separated on SDS-PAGE gradient gels (4-12 % acrylamide; Novex, MES running 
buffer). Samples were suspended in 20 µl of loading buffer containing 60 mM Tris HCl pH 6.8, 2 % 
SDS (w/v), 4 M urea, 5 % glycerol (v/v), 5 mM EDTA, 1 % -mercaptoethanol (v/v) and 0.05 % 
bromophenol blue (w/v) and subjected to heat treatment (100°C, 5 min). Gels were run in duplicate. 
One gel was silver-stained, and the other one was used for Western blot analysis (see below). 
 
3.10- Silver staining 
Silver staining was done according to the manufacturer’s (Proteabio Europe, Langlade, France) 
instructions. Silver-stained gels and Western blot analysis with an anti-CK antibody were used to assess 
the stability of CK after heat treatment. No difference in silver-stained band intensity or 
immunoreactivity was noticed in any experiment.  
 
3.11- Western Blot 
After electrophoretic separation, the gel was electrotransferred onto a polyvinyldifluorene (PVDF) 
membrane (Bio-Rad). PVDF membranes were treated for 30 min with a saturation solution containing 
PBS, 5 % BSA (w/v) and 0.05 % Tween 20 (v/v). Then, PVDF membranes were incubated with the 
3A6 mouse monoclonal anti-morphine primary antibody for 1 h at room temperature (1:1,000). The 
mouse monoclonal 3A6 anti-morphine antibodies (ref AMM00033; Aviva System Biology) were 
raised against a ((5 alpha 6 alpha) 7 8 didehydro-4 5 epoxy-17methylmorphinan-3 5diol)-BSA 
conjugate. Binding of the primary antibody was detected using HRP-conjugated donkey anti-mouse 
antiserum (P.A.R.I.S.; 1:50,000 in PBS, 5 % of BSA (w/v), 0.05 % Tween 20 (v/v)). Luminata 
FORTE™ (Millipore, France) was used as the substrate. Non-specific binding of the secondary 
antibody was ruled out by omitting the primary antibody: non-specific labelling was absent with the 
secondary antibody alone (data not shown). 
 
3.12- Peptide synthesis 
CK-B-derived peptides (73 to 96 residues) were synthesized by Proteogenix (Schiltigheim, France): 
CK-B1-75, CK-B65-140, CK-B127-199, CK-B184-258, CK-B248-343, CK-B286-381, CK-B184-258, CK-B199-223, CK-
B214-238, CK-B228-258. 
 
3.13- Circular dichroism 
Circular dichroism spectra were recorded from 260 to 190 nm using a J-810 spectropolarimeter 
(Jasco, Tokyo, Japan). Spectral resolution and data pitch were adjusted to 1 nm while the scanning 
speed was set up at 50 nm/min. Samples containing 0.2 mg/mL of CK-B1-75 in H2O (pH 6) and CK-
B184-258 (in 2.5 mM of NaOH, pH 7) were transferred into a quartz cuvette of 1 mm path length and 
maintained at the temperature of 23°C. The secondary structures of the peptides were calculated from 
the spectra using a least squares fit procedure implemented in the DicroProt analysis software [20]. 
 
3.14- CK activity assay 
We used a commercial creatine kinase activity assay kit (MAK116, Sigma-Aldrich) to measure the 
potential impact of morphine binding on CK-B enzymatic activity. The protocol followed the 
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manufacturer’s instructions at room temperature. Briefly, 1 µg of rCK-B or 75 µg of brain extract were 
added per well (96 well plates, NUNC) with increasing concentrations of morphine (0, 0.01, 0.1, 1, 10, 
25, 50, 100 µM final). The reconstituted reagent (made of assay buffer, enzyme mix and substrate 
solution) was then added to start the reaction. Fluorescence was recorded using a Mithras LB940 
fluorescence plate reader (Berthold, Bad Wildbad, Germany), with excitation and emission filters of 
350 nm and 460 nm, respectively. Four replicates were used for each data point.  
 
3.15- Statistics 
Data were analyzed using Graphpad Prism Software 7.0. Non-parametric statistical tests were used 
due to low sample size and the non-Gaussian distribution of some groups. For in vitro rCK-B assays, 
data were expressed as percentage of the control (no morphine condition) to account for variability 
across replicates done on separate days. Statistical differences were tested with the Kruskal-Wallis test 
and Dunn’s multiple comparisons as post-hoc. Brain extract assays were analyzed using the Mann-
Whitney U test. Differences between groups were considered statistically significant at p < 0.05. 
 
4- Results  
4.1- Characterization of the CK-B affinity for morphine 
The binding of mouse rCK-B, produced in E. coli to increasing concentrations (1.56 µM to 400 μM) 
of morphine, M3G or M6G was tested by ELISA. The results show that mouse rCK-B binds morphine 
(Figure 1A) with a calculated Kd of 10.8 µM. Our results further revealed that morphine-3-glucuronide 
(M3G), morphine-6-glucuronide (M6G) and codeine only weakly bind to rCK-B (Kd >100 µM) 
compared to morphine. As a non-specific binding control, a series of wells were coated with bovine 
serum albumin (BSA) instead of rCK-B and incubated with increasing concentrations of morphine, 
M3G or M6G. No binding of morphine, M3G or M6G to BSA was observed (Figure 1A, control). 
Together, these results indicate that rCK-B binds morphine with a micromolar range affinity. 
 
4.2- Characterization of a morphine-rCK-B complex resistant to SDS-PAGE 
Mouse rCK-B (0.5 µg) was incubated 15 min in the presence of 1 or 5 µg of morphine. Samples were 
resuspended in loading buffer containing both SDS and urea. A heating step (100°C; 5 min) was 
performed before polyacrylamide gel electrophoresis (PAGE). 
Western blot analysis using anti-morphine antibody showed that the mouse rCK-B alone is not 
labelled by the anti-morphine antibody (Figure 1B, left panel). Morphine immunolabelling was 
observed at 42 kDa (CK-B monomers) and 84 kDa (CK-B dimers) only when CK-B was incubated 
with 1 and 5 µg of morphine. As a control, an identical gel was run in parallel and silver-stained (Figure 
1B, right panel). This control shows the presence of two bands at 42 kDa and 84 kDa in each condition. 
These two bands correspond to the monomers and dimers of mouse rCK-B, respectively. 
These results indicate that morphine-mouse rCK-B complexes are resistant to SDS-PAGE. 
 
4.3- Identification of the CK-B fragments displaying an affinity for morphine 
To identify the morphine-binding motifs of CK, six overlapping peptides, namely CK-B1-75, CK-B65-
140, CK-B127-199, CK-B184-258, CK-B248-343, and CK-B286-381 were tested for morphine, M3G, M6G and 
codeine binding via ELISA (Figure 2A). Increasing concentrations of opiates (0.1 µM to 324 μM) 
were added to wells pre-coated with the peptides (0.5 µg). CK-B1-75 and CK-B184-258 were able to bind 
morphine (Figure 2B-C) with a calculated Kd of 12.5 µM and 13.2 µM, respectively. However, ELISA 
analysis revealed that the six CK-derived peptides have no affinity for M3G, M6G or codeine (Figure 
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2B-C). Circular dichroism analysis revealed that in H2O, CK-B1-75 adopts a structure consisting of 3% 
alpha helix, 15% beta sheets and 82% random coils. Similarly, the predicted secondary structure of 
CK-B184-258 is 8% alpha helix, 19% beta sheets and 73% random coils. Focusing on the CK-B184-258 
peptide, we tested the affinity of four smaller overlapping peptides (CK-B184-258, CK-B199-223, CK-B214-
238, CK-B228-258). None of these four peptides displayed an affinity for morphine using an ELISA 
approach (data not shown).  
Taken together, these results indicate that mouse CK-B1-75 and CK-B184-258 have a micromolar range  
affinity restricted to morphine, as observed for the mouse rCK-B.  
 
4.4- Characterization of the effect of morphine binding on rCK-B activity in vitro 
Next, we measured the potential impact of morphine binding to CK-B on the formation of ATP from 
phosphocreatine. Mouse rCK-B (1 µg) was incubated in the presence of increasing concentrations of 
morphine (0, 0.01, 0.1, 1, 10, 25, 50 and 100 µM; Figure 3A). The activity of rCK-B was monitored 
by measuring the production of ATP during 20 min. Morphine (1 µM) significantly decreased the 
formation of ATP by 27 % (36.4±1.8 nmol/min/mg) compared to the control condition (50 ±1.4 
nmol/min/mg). Further increasing morphine concentrations dose-dependently inhibited CK-B activity 
until a maximal level of inhibition was reached (80% decrease in activity for morphine >50 µM). This 
experiment shows that 1 µM morphine, corresponding to a concentration close to the Kd of CK-B for 
morphine, significantly decreases CK-B activity in vitro.  
 
4.4- Characterization of the effect of morphine on CK-B activity in vivo 
In mice, the effect of morphine on CK-B activity in vivo was measured after a single injection of 
morphine (7.5 mg/kg, i.p.). Endogenous CK-B activity was tested on 75 µg of brain extract, by 
monitoring ATP production over 10 min. Results indicate that acute morphine treatment induces a 
statistically significant decrease of CK-B activity by 15.3% (1.60±0.09 µmole/min/mg of total brain 
protein) compared to saline-treated animals (1.89±0.06 µmole/min/mg of total brain protein; Figure 
3B). 
 
5- Discussion 
The present study reports that recombinant mouse rCK-B displays a micromolar affinity for morphine 
but not for M3G, M6G or codeine. Two morphine-binding sites were identified, namely peptides CK-
B1-75 and CK-B184-258, which displayed a similar micromolar affinity for morphine. In addition, we show 
that CK-B-morphine complexes are resistant to detergents (SDS), chaotropic agents (urea), reducing 
agents and heat treatment. Finally, our results show that at a concentration that results in complex 
formation, morphine significantly decreases the activity of the mouse rCK-B in vitro and endogenous 
mouse brain CK-B in vivo. 
 
5.1- The morphine-CK-B complexes 
CK-B is the main I2B site for imidazoline and derivatives (such as clonidine , guanfacine…) [11; 13; 
14]. In addition, CK was described to covalently bind dopamine [15], which is a morphine precursor 
in plants and animals [1], and to form highly stable complexes with ASB9 [16; 21]. However, the 
potential binding of CK-B to morphine, as well as a potential modulatory role of morphine on CK-B 
activity, have never been studied.  
Covalent binding of morphine to proteins has been first proposed by Misra and colleagues [8; 22]. 
This group was able to demonstrate that a single subcutaneous injection of 10 mg/kg of [14C]-
morphine-N-methyl led to morphine-related radioactivity lasting in the rat CNS for at least 3 weeks. 
Later, [C1-3H]-morphine and [N-14CH3]-morphine were found to irreversibly bind insoluble tissue 
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components after administration [9; 10]. In addition, S-glutathionylmorphine complexes have been 
characterized  [23; 24] and are likely formed first by the action of morphine-6-deshydrogenase (EC 
1.1.1.218) leading to the formation of morphinone [25], followed by a spontaneous step allowing 
conjugation to glutathione (GSH) or proteins displaying cysteine residues. Besides, the binding of 
morphine to 35-50 kDa proteins in mice has also been reported [10; 26; 27]. Morphine binding to these 
unknown proteins was described as “covalent” because morphine-protein complexes were resistant to 
both methanol precipitation and SDS-PAGE denaturing conditions [26]. 
In this article, we similarly unveil the formation of mouse rCK-B-morphine complexes that are 
resistant to SDS-PAGE treatment. Such a strong binding seems incompatible with the micromolar 
range affinity measured by ELISA. However, ELISA only reflects a biased affinity (i) resulting from 
conditions that do not especially promote interactions of morphine with CK-B or its derived fragments 
and (ii) dependent on the primary and secondary antibodies. This point is strengthened by the fact that 
both CK-B1-75 and CK-B184-258 display an affinity (µM range) similar to that of the full-length mouse 
rCK-B. In addition, the control condition performed with a nonspecific morphine-binding protein (i.e., 
BSA) did not result in any binding and therefore highlights the stringency of our ELISA [4; 5].  It is 
likely that morphine-binding sites are present in a well-defined structure of the peptides rather than in 
unstructured parts. Smaller CK-B184-258-derived peptides did not show any affinity for morphine, 
therefore we could not determine a specific morphine-binding site. This suggests that multiple 
structural parts all along the sequence of CK-B184-258 are required for the binding of morphine. The 
formation of strong morphine-CK-B complexes can be explained by two hypotheses: (i) non-covalent 
interactions involving ionic, hydrophobic and/or van der Waals interactions lead to a highly stable 
complex or (ii) a covalent binding of morphine to cysteine residues present in the CK-B occurs. 
However, our in vitro experimental conditions rule out a possible cross-linking involving cysteine 
residues (experiments performed in reducing conditions) and the action of morphine-6-deshydrogenase 
(reaction media do not contain this enzyme). Thus, it is likely that non-covalent complexes are formed 
with morphine and involve specific interactions as shown for the CK-ASB9 complexes [16 ]. 
 
5.2- CK-B activity modulation by morphine 
As CK-B represents a crucial enzyme that regulates ATP bioavailability in the brain, the ability of 
morphine to alter CK-B activity may dramatically affect CNS metabolism. Notably, the binding of the 
irreversible I2B ligand BU99006 (20 µM) to CK-B was shown to decrease the apparent Vmax of CK-
B by up to 16% [14]. However, other I2B ligands (2-BFI, BU224, agmatine) did not affect CK-B 
activity. In addition, it was shown that a chronic administration of cannabidiol increases CK activity 
by up to 20% in the rat brain [28]. 
The implication of I2B sites in the modulation of morphine-induced analgesia has been well 
documented [12; 13; 29; 30] and the involvement of I2B sites in the modulation of morphine 
withdrawal and tolerance has been reported in rodents [31; 32; 33]. For example, the I2 ligand agmatine 
increases morphine-induced analgesia and inhibits tolerance and dependence to opioids [34]. 
In the brain, changes in the expression of energy metabolism enzymes contribute to behavioural 
abnormalities during chronic morphine treatment [35] but can also deeply impact gliotransmission 
through the modulation of ATP release [36]. Accordingly, morphine-binding significantly decreases 
CK-B enzymatic activity by to 27% when morphine is present at a concentration close to the Kd value. 
In addition, we have shown that in vivo, CK-B activity in brain tissue is decreased by 15 % after 
injection of an analgesic dose of morphine. Interestingly, our results are in agreement with the effect 
of morphine on ATP levels in the rat neocortex and thalamus, where respective decreases of 14% and 
26% have been observed in vivo [3].  
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Our results reveal two potential morphine-CK-B binding sites, namely CK-B1-75 and CK-B184-258. The 
former is not involved in CK-B activity. Conversely, CK-B184-258 contains a conserved, negatively 
charged amino acid cluster, Glu226, Glu227, Asp228 (EED) located in the active site of CK isoenzymes 
[37]. This particular motif has been described as essential for CK enzymatic activity. Thus, we can 
hypothesize that morphine alters CK-B function through binding to the CK-B184-258 sequence. A 
limitation of our study is that we only evaluated a fixed time point after euthanizing the animals, and a 
different pattern of CK-B responses might occur at different time points. Further clarification of the 
impact of morphine on CK-B function in vivo is needed, e.g. through brain microdialysis and ATP 
quantification. Another open question is the impact of chronic morphine treatment in patients on CK-
B activity, which is likely to differ from our acute morphine-exposure treatment. Indeed, a chronic 
morphine exposure might inhibit CK-B during a long period leading to important physiological 
changes and a measurable phenotype.  
 
5.3- In vivo complex formation 
After administration, morphine rapidly reaches the CNS where it binds to mu opioid receptors 
(MORs) to produce analgesia. Then, morphine is taken up by glial cells including microglial cells and 
astrocytes through the action of the organic cation transporter OCT1 [38]. After conversion by UDP-
glucuronosyl-transferase (UGT) enzymes [39; 40], glucuronides are released through the efflux MRP3 
transporter (multidrug resistance protein 3) [41]. In this context, it is plausible that after administration 
and cellular uptake, morphine can form complexes with cytoplasmic CK-B and therefore negatively 
modulate its activity. Interestingly, injection (i.v., i.p. or s.c.) of an analgesic dose of morphine (10 to 
20 mg/kg) to mice results in serum concentrations ranging from 2 to 35 µM. Similarly, morphine 
content in the brain reaches nmol/g of tissue levels (corresponding to a µM range), indicating that our 
findings are relevant in vivo [42; 43; 44; 45]. 
Endogenous morphine has been detected in numerous cerebral areas and brain cells of different 
species including the mouse [1; 46; 47]. Specifically, endogenous morphine is detected in GABA-
basket cells, astrocytes and microglial cells [46; 47; 48; 49]. In addition, an increase of endogenous 
morphine and M6G blood levels has been linked to stress [50; 51; 52] and pathologies such as sepsis, 
with concentrations reaching up to 0.25 µM [53; 54]. In contrast to opioidergic peptides (e.g., 
enkephalins), the functional role of endogenous morphine in the CNS remains to be elucidated. 
Endogenous morphine is found in the cytoplasm of astrocytes expressing both OCT1 [55] and CK-B 
[56]. Although endogenous morphine concentrations are unlikely to reach 1 μM, uptake by astrocytic 
processes could theoretically bring endogenous morphine in contact with cytoplasmic CK-B. Whether 
endogenous morphine-CK-B complexes exist and might influence bioavailability of ATP in astrocytes 
and impact ATP-mediated gliotransmission through CK-B inhibition remains to be investigated in 
further studies. 
 
5.4- Clinical relevance of morphine-CK-B interactions 
The in vitro and in vivo impact of morphine on CK-B activity in the mouse raises the question of a 
potential relevance of morphine-CK-B interactions in the case of clinical or recreational use of 
morphine or its derivatives in humans.  
First, doses administered to morphine-naive humans are usually two orders of magnitude lower than 
those needed to elicit analgesia in rodents. Thus, peak morphine blood concentrations (and presumably 
tissue concentrations) after oral therapeutic dosing typically only reach 100 nM [57], a concentration 
far below the 1 µM of morphine needed for CK-B modulation.  
 10
However, it is possible that intracellular morphine could reach micromolar concentrations in 
chronically treated, tolerant patients. Indeed, dose escalation following long-term treatment can lead 
to patients receiving 500 mg of morphine or more per day. Thus, in the case of chronic use of morphine 
or codeine, whether in clinical (e.g. cancer patients) or drug abuse settings, morphine concentrations 
rise to low µM levels in both plasma and brain [58; 59]. In addition, morphine concentrations in the 
cerebrospinal fluid (CSF) and brain extracellular fluid (ECF) have been reported to reach nM to µM 
values in different conditions, including epidural injection during chronic intractable pain due to cancer 
and codeine overdoses [60; 61; 62].  
It is also important to mention the fact that M3G concentrations in these cases are far higher than those 
of morphine. CK-B is an intracellular protein highly expressed in astrocytes which are known to 
metabolize morphine into M3G [63; 64; 65; 66]. The active uptake of morphine by astrocytes might 
allow intracellular morphine to reach µM levels. Unfortunately, intracellular morphine concentrations 
have never been measured in the human brain, although it has been shown in rodents that morphine 
preferentially accumulates inside cells, especially astrocytes rather than in the ECF or CSF [66; 67].  
In conclusion, CK-B/morphine interactions have the potential to be of clinical relevance and this 
warrants further investigation. While morphine concentrations may not reach sufficient levels to 
significantly impact CK-B activity in normal dosing regimens, chronic administration and high doses 
administered to tolerant patients might affect ATP bioavailability in humans. 
 
6- Conclusion 
Taken together, our results unveil a strong interaction between CK-B and morphine, occurring in 
vitro and in vivo. This interaction negatively impacts CK-B activity and thus has the potential to affect 
energy metabolism and glial transmission. Whether or not morphine is able to bind to and modulate 
CK-M or mitochondrial CK remains to be studied, but this seems likely given a high sequence 
homology between these enzymes and CK-B. Additional experiments will allow to further elucidate 
the binding site of morphine and study, in detail, the consequences of this interaction. The impact of 
CK-B and its derived peptides on morphine analgesia and metabolism will be investigated in the future. 
Finally, a detailed study has to focus on endogenous morphine in order to determine its potential 
implication in energy bioavailability in both physiological and pathological processes. 
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Figure 1- Characterization of the CK-B affinity for morphine. A, Affinity of mouse rCK-B for 
morphine, M3G and M6G using an immunoenzymatic assay (ELISA). ELISAs were performed 
with the 3A6 morphine antibody which detects morphine, codeine, M3G and M6G with the same 
affinity. Optical density increases with formation of peptide-alkaloid complexes. Data are expressed 
as mean ± SEM of triplicates (representative result of n=3 independent experiments). B, 
Characterization of CK-B-morphine complexes resistant to SDS-PAGE. Left panel, Western blot 
analysis showing morphine-immunoreactivity after incubation of rCK-B with morphine (representative 
result of n=3 independent experiments). Right panel, silver staining of a duplicate gel performed in 
parallel. 
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Figure 2- Affinity of synthetic peptides generated from mouse CK-B sequence for morphine 
and its derivatives. A, Map of the six CK-B-derived peptides. B, Immunoenzymatic (ELISA) 
determination of the binding properties of peptides CK-B1-75 and CK-B184-258 to morphine, M6G, M3G 
and codeine. Data are expressed as mean ± SEM of triplicates (representative result of n=3 independent 
experiments). ELISAs were performed with the 3A6 anti-morphine antibody which binds morphine, 
codeine, M3G and M6G. Optical density increases with formation of peptide-alkaloid complexes. 
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Figure 3- Effect of morphine on CK-B activity A- In vitro effect of increasing concentrations of 
morphine on CK-B activity. Data are expressed as mean ± SEM. Kruskal-Wallis test with Dunn’s 
multiple comparison; n=8; *, p<0.05;***, p<0.001. B- In vivo effect of an injection of saline or 7.5 
mg/kg of morphine on brain CK-B activity. Data are expressed as mean ± SEM. Mann-Whitney test; 
n=8 animals per group. *, p<0.05. 
 
 
 
